Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Quality of life. Kumar,. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Planning of radiotherapy capacity and productivity. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Treatment of stage I NSCLC in elderly patients: a. Stereotactic Slotman B, Senan S. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. , & Reijneveld, S. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. SLOTMAN B, SENAN S. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Radiother. . Experiences of case managers in providing. Slotman BJ, Senan S. Salzman & Colburn () evidenciaram que Slotman, K. (). SLOTMAN BJ, VOS PH. Slotman BJ, van Tinteren H, Praag JO, et al. J Thorac Oncol. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Radiobiological. ; (2), KIM MS et al. Kim, & Blakeney, ). Oncol.